Table of Contents Author Guidelines Submit a Manuscript
TheScientificWorldJOURNAL
Volume 10 (2010), Pages 2198-2206
http://dx.doi.org/10.1100/tsw.2010.211
Mini-Review Article

Involvement and Therapeutic Potential of the GABAergic System in the Fragile X Syndrome

1Department of Medical Genetics, University of Antwerp, Belgium
2Department of Biological Sciences, Hunter College, New York, NY, USA

Received 21 June 2010; Revised 22 September 2010; Accepted 20 October 2010

Academic Editor: Sergi Ferre

Copyright © 2010 Inge Heulens et al.

Citations to this Article [18 citations]

The following is the list of published articles that have cited the current article.

  • Jeremy Turk, “Fragile X syndrome: lifespan developmental implications for those without as well as with intellectual disability,” Current Opinion In Psychiatry, vol. 24, no. 5, pp. 387–397, 2011. View at Publisher · View at Google Scholar
  • Christina Gross, Elizabeth M Berry-Kravis, and Gary J Bassell, “Therapeutic Strategies in Fragile X Syndrome: Dysregulated mGluR Signaling and Beyond,” Neuropsychopharmacology, vol. 37, no. 1, pp. 178–195, 2011. View at Publisher · View at Google Scholar
  • Liesbeth Rooms, and R. Frank Kooy, “Advances in understanding fragile X syndrome and related disorders,” Current Opinion in Pediatrics, vol. 23, no. 6, pp. 601–606, 2011. View at Publisher · View at Google Scholar
  • H. T. T. Leung, and H. Ring, “Epilepsy in four genetically determined syndromes of intellectual disability,” Journal of Intellectual Disability Research, vol. 57, no. 1, pp. 3–20, 2011. View at Publisher · View at Google Scholar
  • Dejan B. Budimirovic, and Walter E. Kaufmann, “What Can We Learn about Autism from Studying Fragile X Syndrome?,” Developmental Neuroscience, vol. 33, no. 5, pp. 379–394, 2011. View at Publisher · View at Google Scholar
  • S. Hossein Fatemi, and Timothy D. Folsom, “Dysregulation of fragile X mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: A postmortem brain study,” Molecular Autism, vol. 2, no. 1, 2011. View at Publisher · View at Google Scholar
  • S H Fatemi, T D Folsom, R J Rooney, and P D Thuras, “Expression of GABAA α2-, β1- and ɛ-receptors are altered significantly in the lateral cerebellum of subjects with schizophrenia, major depression and bipolar disorder,” Translational Psychiatry, vol. 3, no. 9, pp. e303, 2013. View at Publisher · View at Google Scholar
  • S H Fatemi, T D Folsom, R J Rooney, and P D Thuras, “mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway,” Translational Psychiatry, vol. 3, no. 6, pp. e271, 2013. View at Publisher · View at Google Scholar
  • Eric Lemonnier, Gaëlle Robin, Céline Degrez, Roman Tyzio, Marine Grandgeorge, and Yehezkel Ben-Ari, “Treating Fragile X syndrome with the diuretic bumetanide: a case report,” Acta Paediatrica, vol. 102, no. 6, pp. e288–e290, 2013. View at Publisher · View at Google Scholar
  • Randi J. Hagerman, Vincent Des-Portes, Fabrizio Gasparini, Sebastien Jacquemont, and Baltazar Gomez-Mancilla, “Translating Molecular Advances in Fragile X Syndrome Into Therapy: A Review,” Journal of Clinical Psychiatry, vol. 75, no. 4, pp. E294–E307, 2014. View at Publisher · View at Google Scholar
  • S. Hossein Fatemi, and Timothy D. Folsom, “GABA receptor subunit distribution and FMRP–mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism,” Schizophrenia Research, 2014. View at Publisher · View at Google Scholar
  • Randi J. Hagerman, Baltazar Gomez-Mancilla, Vincent Des-Portes, Fabrizio Gasparini, and Sébastien Jacquemont, “Translating molecular advances in Fragile X syndrome into therapy: A review,” Journal of Clinical Psychiatry, vol. 75, no. 4, pp. e294–e307, 2014. View at Publisher · View at Google Scholar
  • Randi J. Hagerman, Vincent Des-Portes, Fabrizio Gasparini, Sébastien Jacquemont, and Baltazar Gomez-Mancilla, “Translating molecular advances in fragile x syndrome into therapy: A review,” Journal of Clinical Psychiatry, vol. 75, no. 4, pp. e294–e307, 2014. View at Publisher · View at Google Scholar
  • Christina Gross, Anne Hoffmann, Gary J. Bassell, and Elizabeth M. Berry-Kravis, “Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back,” Neurotherapeutics, 2015. View at Publisher · View at Google Scholar
  • Ana Sastre, Nuria E Campillo, Carmen Gil, and Ana Martinez, “Therapeutic approaches for the future treatment of Fragile X,” Current Opinion in Behavioral Sciences, 2015. View at Publisher · View at Google Scholar
  • Tao Yang, Huan Zhao, Changbo Lu, Xiaoyu Li, Yingli Xie, Hao Fu, and Hui Xu, “Synaptic Plasticity, a Prominent Contributor to the Anxiety in Fragile X Syndrome,” Neural Plasticity, vol. 2016, pp. 1–12, 2016. View at Publisher · View at Google Scholar
  • Kaizad Munshi, Katherine Pawlowski, Joseph Gonzalez-Heydrich, and Jonathan D. Picker, “Review of Salient Investigational Drugs for the Treatment of Fragile X Syndrome,” Journal of Child and Adolescent Psychopharmacology, 2017. View at Publisher · View at Google Scholar
  • Jun Wang, Lauren E. Ethridge, Matthew W. Mosconi, Stormi P. White, Devin K. Binder, Ernest V. Pedapati, Craig A. Erickson, Matthew J. Byerly, and John A. Sweeney, “A resting EEG study of neocortical hyperexcitability and altered functional connectivity in fragile X syndrome,” Journal of Neurodevelopmental Disorders, vol. 9, no. 1, 2017. View at Publisher · View at Google Scholar